CannaQ › Blog › Chronic pain
DRAFT – not reviewedCannabis-based medicines and chronic pain: what the systematic reviews say
Two large reviews of randomised trials, including a Cochrane review updated in January 2026, find small or uncertain benefits alongside more frequent side effects.
Key points
- A 2026 Cochrane update (21 trials, 2,187 participants) found no clear evidence that THC-dominant or CBD-dominant medicines increase the number of people with at least 50% relief of neuropathic pain. The certainty of this evidence was very low.[1]
- For balanced THC/CBD medicines, small effects on some outcomes were found with low-certainty evidence, and the authors judged them not clinically relevant.[1]
- A 2021 BMJ meta-analysis (32 trials, 5,174 adults) found small to very small improvements in pain, physical functioning and sleep with non-inhaled medical cannabis or cannabinoids, along with several transient side effects.[3]
- Side effects affecting the nervous system, such as dizziness and drowsiness, were consistently more common than with placebo.[1,3]
Why look at reviews?
Single studies of pain can point in different directions. Systematic reviews collect all eligible randomised trials using a fixed method and rate how certain the combined evidence is (here using the GRADE approach).[1,3] On CannaQ's evidence scale, they sit at the top, but only as strong as the trials they include.
Chronic neuropathic pain: the 2026 Cochrane update
The review notes that its estimated population prevalence ranges from 6% to 10%, and that current medicines help only a minority.[1] The 2026 update replaced the 2018 version of the same review.[1,2] It searched the literature up to 29 January 2025 and included 21 double-blind randomised trials with 2,187 adults, lasting 2 to 26 weeks.[1] The authors judged overall risk of bias to be low in six studies, unclear in ten and high in five.[1]
| Type of medicine vs placebo | What the review concluded | Certainty |
|---|---|---|
| THC-dominant | No clear evidence for an effect on pain relief of 50% or more, global improvement, withdrawals due to side effects or serious side effects. May increase nervous-system side effects. | Very low (benefit outcomes); low (nervous-system side effects) |
| Balanced THC/CBD | No clear evidence for pain relief of 50% or more. May slightly increase "much improved" ratings, 30% pain relief and withdrawals due to side effects; the authors judged these effects not clinically relevant. | Very low to low |
| CBD-dominant | No clear evidence for an effect on pain relief of 50% or more. Other outcomes could go either way. | Very low to low |
Source for this table: the abstract of the Cochrane review.[1] The review reported no funding.[1]
Chronic pain more broadly: the 2021 BMJ meta-analysis
This review included 32 randomised trials with 5,174 adults with chronic non-cancer pain (28 trials) or cancer-related pain (4 trials). Cannabis was given orally (30 trials) or applied to the skin (2 trials), with follow-up of 1 to 5.5 months.[3]
- Pain: compared with placebo, non-inhaled medical cannabis probably leads to a small increase in the share of people reaching a minimally important improvement in pain: about 10 percentage points more (95% CI 5 to 15; moderate certainty).[3]
- Function and sleep: a very small improvement in physical functioning and a small improvement in sleep quality (high certainty), with no improvement in emotional, role or social functioning (high certainty).[3]
- Side effects: a small increased risk of transient cognitive impairment, vomiting, drowsiness, impaired attention and nausea (moderate certainty), and a greater increase in dizziness, which was larger in trials lasting 3 months or more.[3]
The review's own disclosures list relationships of some authors with cannabis companies.[3] Readers can check these in the original publication.
Limits of the evidence
- Most trials were short, lasting weeks to a few months, so long-term benefits and harms remain unclear.[1,3]
- The 2018 Cochrane review noted that trials often excluded people with a history of substance use problems or other significant illnesses, which limits how well results apply to everyday patients.[2]
- The two reviews asked different questions (neuropathic pain only, versus chronic pain in general and non-inhaled products) and should not be read as contradicting each other.
- The BMJ review's estimates concern non-inhaled (oral or topical) products only.[3]
Ongoing research
On 2026-11-17, a ClinicalTrials.gov search for currently recruiting studies of cannabinoids in neuropathic pain returned three registered trials, including a phase 2 proof-of-concept trial run by the US VA Office of Research and Development and a pilot study of cannabidiol in diabetic peripheral neuropathy.[4,5,6] Registration does not mean results exist yet.
References
All identifiers below were retrieved and checked on 2026-11-17 through PubMed E-utilities, the Europe PMC REST API and the ClinicalTrials.gov API v2.
- Ateş G, Welsch P, Klose P, Phillips T, Lambers B, Häuser W, Radbruch L. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2026;1(1):CD012182. PMID: 41548880. DOI: 10.1002/14651858.CD012182.pub3.
- Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3(3):CD012182. (Superseded by reference 1.) PMID: 29513392. DOI: 10.1002/14651858.CD012182.pub2.
- Wang L, Hong PJ, May C, et al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ. 2021;374:n1034. PMID: 34497047. DOI: 10.1136/bmj.n1034.
- ClinicalTrials.gov. Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain. Phase 2; recruiting (checked 2026-11-17). NCT05351801.
- ClinicalTrials.gov. Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study. Phase 1/2; recruiting (checked 2026-11-17). NCT07298408.
- ClinicalTrials.gov. Brain Mechanisms Supporting Cannabis-induced Pain Relief. Early phase 1; recruiting (checked 2026-11-17). NCT04982965.
CannaQ